Regenerative medicine · Longevity

Restoring the biology that disease takes away.

Restoring balance. Reclaiming health. Extending healthspan.

Modern medicine has learned to slow disease. It has rarely learned to undo it. A new generation of regenerative biology is changing that — repairing, resetting, and rebuilding the systems that age and illness break down.

YZR Biotech is an investment platform built to back it, across the United States, Europe, and the Gulf.

Get in touch →

Regenerative Medicine · Cell Therapy · Gene Editing · Longevity Science · Precision Health · AI-Enabled Biology · Regenerative Medicine · Cell Therapy · Gene Editing · Longevity Science · Precision Health · AI-Enabled Biology ·

Why it matters

Chronic and age-related disease is the defining health challenge of our time — and for all our spending, we still mostly manage decline rather than reverse it.

The shortfall is not effort. It is approach. Most medicine modulates a broken process; few interventions restore the body's own capacity to repair. The cost is counted in both lives and trillions.

No cure for the mindAfter 200+ Alzheimer's trials, there is still no cure — while neurodegenerative disease has more than doubled in a generation.
No repair for the heartCardiovascular disease remains the world's leading cause of death, yet no medicine rebuilds the heart after an attack.
No reset for immunityRoughly 70% of disease traces to inflammation, but we treat the symptoms — and 100M+ people live with autoimmunity that nothing resets.

Each is a failure of repair. That is precisely what regenerative medicine is built to solve.

Why now

A generational tipping point.

Three forces are converging at once — the science, the need, and the capital — turning regenerative medicine from promise into an investable category.

The science is ready

Cell and gene therapy now has the manufacturing, delivery, and regulatory paths it lacked a decade ago — and AI is compressing discovery from years to months.

The need is urgent

Aging populations and chronic disease are creating a multi-trillion-dollar burden that today's medicine can only hold at bay.

The capital is aligned

Long-horizon sovereign and family capital, particularly across the Gulf, matches the decades-long arc of regenerative medicine.

$12T

GDP added by 2040

$2T+

Annual healthcare savings

40M+

Life-years gained yearly

The projected impact of healthspan-extending medicine by 2040 — the scale of value that regenerative biology stands to unlock.Source: WHO (2022) · McKinsey & Company (2022) · UN Population Division (2023)

The thesis

Rewire. Reprogram. Replace.

We invest in mechanism-driven biology that goes beyond modulation to rebalance the body at the cellular level. Three strategies define where we look.

Rewire

Correct the code

Precise genome editing restores genetic homeostasis by correcting the mutations that drive disease.

Science, 2022

Reprogram

Reset the cell

Returning aged or diseased cells to healthier states rejuvenates tissue and restores function at its root.

Cell, 2014

Replace

Rebuild the tissue

New, functional cells take over lost capability and restore physiological relevance where biology has failed.

Nature, 2025

One approach, applied across cardiovascular, metabolic, neurological, immune, and oncologic disease — wherever biology can be brought back online.

Approach

We are more than capital.

We partner early — backing the strongest Seed to Series B teams, and creating ventures ourselves — to architect, launch, and scale companies with durable scientific and commercial foundations. Operator-led and institutionally connected, we shape strategy, recruit leadership, and align the capital and partnerships that carry a program to its next inflection.

Biology firstFirst-in-class and first-in-human programs with deep mechanistic rationale — chosen for the science, not the hype.
Hands-on company buildingWe shape teams and execution to de-risk science and accelerate development from the ground up.
Institutionally connectedA network spanning pharma, academic medicine, and sovereign, corporate, and family-office capital.

2008

Health-tech family office

2021

Institutional venture fund

2026

Regenerative medicine & longevity

Leadership

The people behind the platform.

Complementary backgrounds, pioneering health-tech and biotech for more than fifteen years.

Dr. Faizzan Ahmad

Co-Founder & Managing Partner

Faizzan is Co-Founder and Managing Partner of YZR Capital Biotech. An Oxford-trained scientist and biotech investor, he focuses on regenerative medicine, AI-enabled biology, precision health, and longevity. Previously he was an Investment Director at Cambrian BioPharma, where he helped build, finance, and scale companies across cell therapy, gene therapy, and aging biology, including Vita Therapeutics. Across his biotech track record he has invested more than $90 million, and was mentored by leaders in the field such as Prof. Lorenz Studer and Sir Magdi Yacoub. He holds a DPhil from the University of Oxford, where his research focused on cardiovascular pharmacology and stem cell biology.

New York · Doha

Prof. Dr. Reinhard Meier

Co-Founder & Managing Partner

Reinhard is Co-Founder and Managing Partner of YZR Capital Biotech. A healthcare entrepreneur, venture investor, and Professor of Medicine, he brings more than 20 years of experience at the intersection of medical practice, innovation, and capital formation. He co-founded a leading telemedicine platform that exited to a public company in 2020, and has spent more than 15 years investing across venture, growth, and buyout strategies in healthcare. He combines a clinical perspective with institutional investment discipline in building and scaling healthcare companies.

Doha · Munich

Venture & Operating Team — Fund III

Jan Adams, PhD

Founding Venture Partner

20+ years in Private Equity & Venture Capital. Former Apollo Health Partner. Scientific Ventures & Deep Tech GP, Max Planck €80M Life Science Fund. >$350M raised, >3× TVPI, 2 NASDAQ IPOs (Apellis, Arsanis).

Max Jahn

Venture Partner

15+ years in Venture Capital & Family Office advisory. Ex-R&R Ventures (Ron Lauder & Dick Parsons). $500M+ structured across family-office and sovereign LPs, with focus on fund architecture and capital formation.

Andy Feng

Founding Principal

10+ years in Biotech VC & Valuation. Built rNPV models and portfolio strategies across regenerative medicine and oncology.

Khalifa ElMagarmid

Founding Associate

Emerging leader in Qatar's R&D and innovation ecosystem. Supporting YZR Capital's biotech platform with focus on strategic partnerships and local ecosystem growth in Doha.

Global Board of Directors

H.E. Sheikh Mansoor Bin Khalifa Al-Thani

MBK Holding · Founding Chairman

20+ years as Entrepreneur & Venture Capital Investor. Founding Chairman of YZR Capital, driving global biotech innovation and long-term ecosystem development.

Sultan Almaadeed

ONX Platform

Qatar-based entrepreneur and connector building cross-border platforms across the Gulf innovation ecosystem.

Gregory Bailey, MD

Juvenescence

Chairman, Juvenescence. Serial biotech entrepreneur whose companies delivered multiple $10B+ outcomes, including Biohaven and Medivation.

Dr. Marc Thom

Henkel Ventures

Corporate venture pioneer across Henkel and Sony Ventures, with deep health-capital and platform-scaling expertise.

Michael Bitzer, MD

Daman Health

Founder & former CEO of Daman Health, the UAE's pioneering national insurer. A global health-finance leader.

Elmar Willebrand

Healthcare Systems

Former CEO of Asklepios, a leading European hospital group. Specialist in healthcare system scaling and operations.

Marcia-Elizabeth C. Favale

QIC — Qazaqstan Investment Corporation

Board Director at QIC. Expert in private capital, finance, impact investing, and frontier markets.

Gen Tsuchikawa

Sony Ventures

Founder-CEO of Sony Ventures. Global CVC architect and cross-border innovation strategist.